Mallinckrodt Creating Two Companies: Generics And Innovative Specialty Drugs
Executive Summary
The company, which makes generic opioid products and the controversial Acthar Gel, is looking to chart a new course for the future – or make that two new courses.
You may also be interested in...
Mallinckrodt Finds An Exit Door For Generics In Proposed Opioid Settlement
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.
Opioid Exposure Risk Intensifying For Generic Drug Makers
Business fundamentals took a back seat to opioid litigation in the second quarter for generic drug makers, including Teva, Mallinckrodt and Endo Pharmaceuticals.
Biopharma Quarterly Dealmaking Statistics, Q4 2018
At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.